Latest VR Adviser, LLC Stock Portfolio
VR Adviser, LLC Performance:
2024 Q4: -10.73%YTD: 4.4%2023: 5.35%
Performance for 2024 Q4 is -10.73%, and YTD is 4.4%, and 2023 is 5.35%.
About VR Adviser, LLC and 13F Hedge Fund Stock Holdings
VR Adviser, LLC is a hedge fund based in NEW YORK, NY. On 30-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $2.4 Billions. In it's latest 13F Holdings report, VR Adviser, LLC reported an equity portfolio of $1.5 Billions as of 31 Dec, 2024.
The top stock holdings of VR Adviser, LLC are , OCUL, . The fund has invested 26.4% of it's portfolio in APOGEE THERAPEUTICS INC and 7.5% of portfolio in OCULAR THERAPEUTIX INC.
The fund managers got completely rid off EDGEWISE THERAPEUTICS INC (EWTX), ARVINAS INC (ARVN) and ADVERUM BIOTECHNOLOGIES INC (ADVM) stocks. They significantly reduced their stock positions in TERNS PHARMACEUTICALS INC (TERN), TAYSHA GENE THERAPIES INC (TSHA) and TREVI THERAPEUTICS INC (TRVI). VR Adviser, LLC opened new stock positions in UPSTREAM BIO INC, CIDARA THERAPEUTICS INC (CDTX) and GLYCOMIMETICS INC (GLYC). The fund showed a lot of confidence in some stocks as they added substantially to ENGENE HOLDINGS INC, PRAXIS PRECISION MEDICINES I (PRAX) and APPLIED THERAPEUTICS INC (APLT).
The top stock holdings of VR Adviser, LLC are , OCUL, . The fund has invested 26.4% of it's portfolio in APOGEE THERAPEUTICS INC and 7.5% of portfolio in OCULAR THERAPEUTIX INC.
The fund managers got completely rid off EDGEWISE THERAPEUTICS INC (EWTX), ARVINAS INC (ARVN) and ADVERUM BIOTECHNOLOGIES INC (ADVM) stocks. They significantly reduced their stock positions in TERNS PHARMACEUTICALS INC (TERN), TAYSHA GENE THERAPIES INC (TSHA) and TREVI THERAPEUTICS INC (TRVI). VR Adviser, LLC opened new stock positions in UPSTREAM BIO INC, CIDARA THERAPEUTICS INC (CDTX) and GLYCOMIMETICS INC (GLYC). The fund showed a lot of confidence in some stocks as they added substantially to ENGENE HOLDINGS INC, PRAXIS PRECISION MEDICINES I (PRAX) and APPLIED THERAPEUTICS INC (APLT).
VR Adviser, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that VR Adviser, LLC made a return of -10.73% in the last quarter. In trailing 12 months, it's portfolio return was 4.4%.
New Buys
| Ticker | $ Bought |
|---|---|
| upstream bio inc | 37,735,000 |
| cidara therapeutics inc | 20,582,600 |
| glycomimetics inc | 747,000 |
New stocks bought by VR Adviser, LLC
Additions
| Ticker | % Inc. |
|---|---|
| engene holdings inc | 41.52 |
| praxis precision medicines i | 40.2 |
| oruka therapeutics inc | 6.48 |
| applied therapeutics inc | 1.69 |
| cogent biosciences inc | 0.00 |
Additions to existing portfolio by VR Adviser, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| terns pharmaceuticals inc | -68.41 |
| taysha gene therapies inc | -64.16 |
| trevi therapeutics inc | -63.00 |
| aquestive therapeutics inc | -52.66 |
| merus n v | -34.75 |
| 4d molecular therapeutics in | -32.9 |
| astria therapeutics inc | -28.95 |
| century therapeutics inc | -26.57 |
VR Adviser, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cabaletta bio inc | -7,381,850 |
| adverum biotechnologies inc | -10,298,700 |
| edgewise therapeutics inc | -26,690,000 |
| arvinas inc | -11,193,100 |
VR Adviser, LLC got rid off the above stocks
Sector Distribution
VR Adviser, LLC has about 51.6% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 51.6 |
| Healthcare | 48.4 |
Market Cap. Distribution
VR Adviser, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 51.6 |
| SMALL-CAP | 39.8 |
| MID-CAP | 5.2 |
| MICRO-CAP | 3.2 |
Stocks belong to which Index?
About 34% of the stocks held by VR Adviser, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 66 |
| RUSSELL 2000 | 34 |
VR Adviser, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of VR Adviser, LLC
VR Adviser, LLC has 37 stocks in it's portfolio. About 70.5% of the portfolio is in top 10 stocks. APLT proved to be the most loss making stock for the portfolio. PRAX was the most profitable stock for VR Adviser, LLC last quarter.
Last Reported on: 14 Feb, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| apogee therapeutics inc | 26.40 | 8,493,320 | 384,747,000 | unchanged | 0.00 | |||
| OCUL | ocular therapeutix inc | 7.48 | 12,762,500 | 108,991,000 | unchanged | 0.00 | ||
| enliven therapeutics inc | 6.22 | 4,026,330 | 90,592,400 | unchanged | 0.00 | |||
| PRAX | praxis precision medicines i | 5.23 | 989,985 | 76,189,200 | added | 40.2 | ||
| VRDN | viridian therapeutics inc | 5.11 | 3,882,710 | 74,431,500 | unchanged | 0.00 | ||
| oruka therapeutics inc | 4.37 | 3,285,620 | 63,708,200 | added | 6.48 | |||
| AGLE | spyre therapeutics inc | 4.29 | 2,685,450 | 62,517,200 | unchanged | 0.00 | ||
| PHVS | pharvaris n v | 4.24 | 3,220,130 | 61,729,900 | reduced | -5.17 | ||
| KALV | kalvista pharmaceuticals inc | 3.63 | 6,249,730 | 52,935,200 | unchanged | 0.00 | ||
| DYN | dyne therapeutics inc | 3.51 | 2,173,910 | 51,217,400 | unchanged | 0.00 | ||
| COGT | cogent biosciences inc | 3.04 | 5,684,410 | 44,338,400 | added | 0.00 | ||
| ERAS | erasca inc | 2.79 | 16,216,200 | 40,702,700 | unchanged | 0.00 | ||
| dianthus therapeutics inc | 2.61 | 1,744,370 | 38,027,300 | unchanged | 0.00 | |||
| upstream bio inc | 2.59 | 2,295,320 | 37,735,000 | new | ||||
| ORIC | oric pharmaceuticals inc | 2.43 | 4,394,530 | 35,463,800 | unchanged | 0.00 | ||
| engene holdings inc | 2.30 | 5,046,410 | 33,558,700 | added | 41.52 | |||
| MRUS | merus n v | 1.71 | 592,411 | 24,910,900 | reduced | -34.75 | ||
| ATXS | astria therapeutics inc | 1.51 | 2,457,350 | 21,968,700 | reduced | -28.95 | ||
| CDTX | cidara therapeutics inc | 1.41 | 765,723 | 20,582,600 | new | |||
| CGEM | cullinan therapeutics inc | 1.15 | 1,379,960 | 16,808,000 | unchanged | 0.00 | ||
